Diffuse large B-cell lymphoma (DLBCL) represents 30-40% of all newly diagnosed cases of non-Hodgkin lymphoma (NHL). Chemoimmunotherapy with R-CHOP is curative in 50-60% of cases but most patients failing frontline therapy will perish to their disease, including those eligible for autologous stem cell transplantation (SCT) [1] . Chimeric antigen receptors (CARs) are synthetic protein constructs that contain an extracellular tumor antigen binding domain and intracellular activating elements, including a costimulatory domain such as 4-1BB or CD28 [2] . The choice of costimulatory domain impacts persistence (months for CD28 vs years for 4-1BB) and expansion (favored by CD28) in vivo [2] . CD19-targeted CAR T cells have proven effective in relapsed/refractory DLBCL. Two CARs, axicabtagene ciloleucel (axi-cel, Yescarta TM , Gilead) and tisagenlecleucel (Kymriah TM , Novartis) are approved in that setting and a third one, lisocabtagene maraleucel (liso-cel, Celgene), has generated promising preliminary data. Despite differences in costimulatory molecules, dosing, lymphodepletion, bridging therapy, patient population, and length of followup, multicenter trials have reported robust efficacy with all 3 CARs (Table 1) .
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In the pivotal ZUMA-1 trial, axi-cel was administered to 108 patients with refractory aggressive NHL [3] . T-cell products were manufactured with a 99% success rate and infused after a median of 17 days postleukapheresis. Hospitalization was required for at least 7 days post-infusion for toxicity monitoring. The best ORR was 82% and the best CR was 58%. After a median follow-up of 15.4 months, 42% of patients continue to respond (40% in CR) and the OS rate at 18 months was 52% [3] . CRS occurred in 93% of patients (grade ≥3 in 13%) whereas neurotoxicity occurred in 64% of patients (grade ≥3 in 28%) [3] . Three axi-cel related deaths, including 2 due to severe CRS, were reported [3] .
In the pivotal JULIET study, 99 patients with relapsed/refractory DLBCL received tisagenlecleucel [4] . Drop-out rates were high as tisagenlecleucel could only be given to 67% of enrolled patients. The best ORR and CR rates were 53% and CR 40%, respectively. The 6-month RFS was 74% and the median OS was not reached. CRS occurred in 58% of patients (grade 3/4 in 23%) and grade 3/4 neurotoxicity occurred in 12% of patients, but neither complication was fatal [4] .
The TRANSCEND NHL-001 trial tested liso-cel at a fixed 1:1 CD4:CD8 ratio at two dose levels (5×10 7 and 1×10 8 cells) [5] . In the FULL dataset (n = 91), the best ORR was 74% and best CR rate was 52%. In the CORE dataset (n = 67), including only high-grade B-cell lymphoma (double/triple hit), DLBCL not otherwise specified either de novo or transformed from follicular lymphoma, the best ORR and CR rates were 80% and 55%. Grade 3/4 CRS and neurotoxicity rates were only 1% and 15%, respectively but 60% of patients had none of those toxicities, thus supporting the investigation of outpatient administration [6] .
CD19-directed CARs improve upon salvage therapy for patients with DLBCL who have failed at least 2 lines of therapy [1] . The SCHOLAR-1 study reported an ORR of 26% and CR rate of 7% with standard salvage therapy in patients with refractory aggressive NHL [1] . Liso-cel appears to render a higher CR rate than axi-cel or tisagenlecleucel but longer follow-up in a pivotal trial is warranted to confirm these findings. Tisagenlecleucel and axi-cel are only available through Risk Evaluation and Mitigation Strategy (REMS) programs as severe CRS and/ or neurotoxicity afflict a significant number of patients, particularly those with high baseline tumor burden and/or levels of inflammation markers. The latter may provide a means to better select patients to minimize on-target/offtumor toxicity. While axi-cel has been the first CAR T cell approved in DLBCL, this competitive advantage may be offset by the approval of safer options. Tisagenlecleucel is associated with a higher risk of severe CRS but lower risk of severe neurotoxicity and lesser tocilizumab usage than axi-cel. However, tisagenlecleucel has been associated with high drop-out rates, partly due to manufacturing inefficiencies leading to prolonged vein-to-vein times. Liso-cel appears to exhibit the safest toxicity profile of all available CD19-directed CARs (severe CRS rate 1%), and the potential for outpatient administration. If these preliminary results are confirmed in an ongoing pivotal trial and its vein-to-vein time is similar to that of axi-cel, it might become the best-in-class CAR product for DLBCL.
These studies have demonstrated the feasibility of manufacturing personalized cell therapies at a centralized facility and its delivery at a global scale. Nevertheless, only a few hundred patients with DLBCL have received CAR T cell therapy thus far, and all of them in the context of single-arm, uncontrolled studies with limited followup. The latter prevents making conclusions regarding the potential curative potential of these therapies, their longterm toxicity, and their activity compared to standard Editorial www.oncotarget.com chemoimmunotherapy or autologous SCT. These are key considerations given the $373,000 price tag attached to both tisagenlecleucel and axi-cel. Since 7,500 patients with relapsed/refractory DLBCL are eligible for CAR T cell therapy, the total expenditure in the U.S. alone would exceed $3B [7] . Improvements in T cell leading to improved efficacy, lower CRS/neurotoxicity rates and severity that enable outpatient administration, a better understanding of the pathophysiology of those toxicities, and improved cheaper manufacturing processes represent the immediate challenges to improve current CAR T cell therapies.
